Literature DB >> 3365042

Balloon valvuloplasty in calcified aortic stenosis: a cause for caution and alarm.

F Robicsek1, N B Harbold, H K Daugherty, J W Cook, J G Selle, P J Hess, J J Gallagher.   

Abstract

Balloon dilation by the percutaneous route has recently been recommended as an alternative to surgical intervention in the management of calcified aortic valvular stenosis. To investigate the validity of balloon valvuloplasty, this procedure was carried out in the operating room under direct vision in 30 patients just prior to excision and replacement of the ossified aortic valve. Changes induced by balloon dilation were evaluated by visual inspection as well as by geometric measurements. By visual observation, balloon valvuloplasty did not have a detectable impact on the valvular anatomy in about 19 of the patients and induced enlargement of the functional aortic orifice judged as "minimal" or "moderate" in only 11. In no patient was there a substantial increase in the functional orifice size. These findings were supported by geometrical measurements. Therefore, we believe that the virtues of this procedure have been grossly overstated by its proponents and that it should be offered only to patients who present a truly forbidding risk by standards of modern surgery.

Entities:  

Mesh:

Year:  1988        PMID: 3365042     DOI: 10.1016/s0003-4975(10)64524-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Balloon aortic valvuloplasty: the Texas Heart Institute experience.

Authors:  J J Ferguson; E P Riuli; A Massumi; B Treistman; S K Edelman; M V Harlan; S E Brasier; J P Murgo
Journal:  Tex Heart Inst J       Date:  1990

2.  Continuous recording of vital signs with a wearable device in pediatric patients undergoing chemotherapy for cancer-an operational feasibility study.

Authors:  Christa Koenig; Roland A Ammann; Claudia E Kuehni; Jochen Roessler; Eva Brack
Journal:  Support Care Cancer       Date:  2021-03-03       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.